VERZENIO® (abemaciclib) Receives Positive Reimbursement Recommendation from Canadian Agency for Drugs and Technologies in Health (...
TORONTO, Oct. 31, 2022 /CNW/ - Lilly Canada announced today that the Canadian Agency for Drugs and Technologies in Health (CADTH) has issued their final reimbursement recommendation for VERZENIO® (abemaciclib) in early breast cancer. CADTH recommends that …